AGL
agilon health, inc. · Healthcare · Medical Care Facilities
Last
$92.48
+$0.20 (+0.21%) 3:59 PM ET
After hours $92.54 +$0.06 (+0.07%) 4:51 AM ET
Prev close $92.28
Open $92.37
Day high $92.64
Day low $88.07
Volume 156,870
Avg vol 529,890
Mkt cap
$1.54B
P/E ratio
-4.29
FY Revenue
$5.82B
EPS
-21.56
Gross Margin
-2.50%
Sector
Healthcare
AI report sections
AGL
agilon health, inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
−56% (Below avg)
Vol/Avg: 0.44×
RSI
79.47 (Overbought)
Overbought (>70)
MACD momentum
Intraday
+0.04 (Strong)
MACD: 0.28 Signal: 0.23
Short-Term
+0.69 (Strong)
MACD: 16.00 Signal: 15.31
Long-Term
+2.39 (Strong)
MACD: 22.13 Signal: 19.74
Intraday trend score 60.00

Latest news

AGL 12 articles Positive: 1 Neutral: 0 Negative: 11
Positive Benzinga • Piero Cingari
7 Small-Cap Stocks More Than Doubled In May: Micron Did Only 46%

Seven Russell 2000 small-cap stocks more than doubled in May 2026, significantly outperforming Micron Technology's 46% gain. The rallies were driven by specific catalysts including strong earnings reports, guidance raises, strategic partnerships, and defense contracts. Hyliion Holdings led with a 213.6% gain, followed by Agilon Health at 209.1%, with each company benefiting from positive business developments and analyst upgrades.

HYLN AGL RXT EVC small-cap stocks Russell 2000 earnings catalysts AI demand
Sentiment note

Stock rallied 209.1% following stronger Q1 profitability, raised full-year 2026 guidance, and Deutsche Bank upgrade to Buy. The gap-up opening and sustained climb through the month indicate strong investor confidence in the senior-care company's trajectory.

Negative GlobeNewswire Inc. • Levi & Korsinsky, Llp
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 2, 2026 in agilon health, inc. Lawsuit – AGL

Law firm Levi & Korsinsky notifies investors of class action securities lawsuits against agilon health, inc., Ardent Health, Inc., and Zynex, Inc. The primary case involves agilon health for alleged securities fraud between February 26, 2025 and August 4, 2025, with claims that defendants issued false 2025 guidance and overstated financial impacts from strategic actions. Lead plaintiff deadlines range from March 2 to April 21, 2026.

AGL ARDT class action lawsuit securities fraud lead plaintiff false guidance investor losses materiality
Sentiment note

Company is subject to securities fraud allegations involving false 2025 guidance, material overstatement of financial impacts, and concealment of industry headwinds. Investors suffered losses during the relevant period.

Negative GlobeNewswire Inc. • The Law Offices Of Frank R. Cruz
DEADLINE ALERT for AGL, FRMI, VRNS, and ARDT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Law Offices of Frank R. Cruz has announced class action lawsuits against four publicly-traded companies for allegedly making materially false and misleading statements to investors. Agilon Health is accused of issuing unachievable 2025 guidance; Fermi Inc. of overstating tenant demand for Project Matador; Varonis Systems of failing to disclose growth trajectory challenges; and Ardent Health of misrepresenting accounts receivable practices and insurance coverage. Lead plaintiff deadlines range from March 2-9, 2026.

AGL FRMI VRNS ARDT class action lawsuit securities fraud misleading statements shareholder losses
Sentiment note

Company accused of issuing false 2025 guidance despite known industry headwinds and overstating financial impact of strategic actions, indicating management misrepresentation to investors.

Negative GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.
AGILON CLASS ACTION DEADLINE MARCH 2nd: Bragar Eagel & Squire, P.C. Urgently Reminds Agilon Health Investors with Large Losses to Contact the Firm Before the Lead Plaintiff Deadline

A class action lawsuit has been filed against Agilon Health, Inc. (NYSE: AGL) for allegedly making false and misleading statements regarding 2025 guidance and overstating financial impacts from strategic actions. Investors who purchased Agilon securities between February 26, 2025 and August 4, 2025 have until March 2, 2026 to apply as lead plaintiff.

AGL class action lawsuit securities fraud false guidance investor losses lead plaintiff deadline misleading statements
Sentiment note

The company is accused of issuing false 2025 guidance, overstating financial impacts from strategic actions, and making materially misleading statements about its business operations and prospects, resulting in investor losses.

Negative GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc
Bronstein, Gewirtz & Grossman LLC Urges agilon health, inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against agilon health, inc. alleging that company executives made false and misleading statements regarding 2026 guidance and overstated the financial impact of strategic risk reduction actions during the period from February 26, 2025 to August 4, 2025. Investors who purchased agilon securities during this period are encouraged to join the case, with a lead plaintiff deadline of March 2, 2026.

AGL class action lawsuit securities fraud false guidance investor harm lead plaintiff federal securities laws
Sentiment note

Company is accused of issuing false 2026 guidance, overstating financial benefits from strategic actions, and making materially misleading statements about business operations and prospects, resulting in investor losses.

Negative GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.
AGILON DEADLINE MARCH 2nd: Bragar Eagel & Squire, P.C. Urgently Reminds Agilon Health Investors with Larges Losses to Contact the Firm Before the Lead Plaintiff Deadline

A class action lawsuit has been filed against Agilon Health, Inc. for allegedly making false and misleading statements regarding 2025 guidance and overstating financial impacts from strategic actions. Investors who purchased Agilon securities between February 26, 2025 and August 4, 2025 have until March 2, 2026 to apply as lead plaintiff.

AGL class action lawsuit securities fraud misleading statements investor losses lead plaintiff deadline false guidance
Sentiment note

The company is accused of issuing false 2025 guidance, overstating financial impacts from strategic actions, and making materially misleading statements about its business operations and prospects, resulting in investor losses.

Negative GlobeNewswire Inc. • Pomerantz Llp
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in agilon health, inc. of Class Action Lawsuit and Upcoming Deadlines - AGL

Pomerantz Law Firm has filed class action lawsuits against agilon health, inc. and other companies for alleged securities fraud. Agilon's CEO stepped down on August 4, 2025, and the company suspended its 2025 financial guidance, citing acute industry headwinds. The stock fell 51.52% to $0.88 per share on August 5, 2025. Investors have until March 2, 2026 to request Lead Plaintiff status.

AGL class action lawsuit securities fraud CEO resignation financial guidance suspension stock price decline
Sentiment note

CEO departure, suspension of full-year 2025 financial guidance, acknowledgment of worse-than-expected industry headwinds, and a dramatic 51.52% stock price decline indicate significant operational and financial challenges, along with alleged securities fraud.

Negative GlobeNewswire Inc. • Rosen Law Firm
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages PomDoctor Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - POM

Rosen Law Firm is soliciting investors who purchased securities in PomDoctor Ltd., Richtech Robotics Inc., and agilon health, inc. during specified periods to join class action lawsuits. The firm alleges that PomDoctor was subject to fraudulent stock promotion schemes and misleading statements, while similar allegations are being pursued against the other companies. The lead plaintiff deadline for PomDoctor is April 7, 2026.

POM RR AGL securities class action fraudulent stock promotion misleading statements lead plaintiff deadline investor compensation
Sentiment note

Company is subject to securities class action lawsuit with the firm specifically targeting investors with losses exceeding $100,000, indicating material investor harm.

Negative GlobeNewswire Inc. • Rosen Law Firm
ROSEN, THE FIRST FILING FIRM, Encourages Richtech Robotics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – RR

Rosen Law Firm has filed securities class action lawsuits against Richtech Robotics Inc. (RR), PomDoctor Ltd. (POM), and agilon health, inc. (AGL). The primary case involves Richtech Robotics, which allegedly made false statements about having a collaborative relationship with Microsoft. Investors who purchased securities during specified class periods are encouraged to seek counsel before upcoming deadlines, with the lead plaintiff deadline for Richtech set for April 3, 2026.

RR POM AGL securities class action Richtech Robotics PomDoctor Ltd. agilon health false statements
Sentiment note

Company is subject to a securities class action lawsuit with the firm specifically noting investors with losses in excess of $100K, indicating significant alleged securities violations.

Negative GlobeNewswire Inc. • Rosen Law Firm
AGILON DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages agilon health, inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AGL

Rosen Law Firm is soliciting investors who purchased securities of Agilon Health (AGL) between February 26, 2025 and August 4, 2025 to join a securities class action lawsuit. The firm alleges that Agilon made false and misleading statements regarding 2025 guidance, overstated financial impacts from strategic actions, and failed to disclose material industry headwinds. The lead plaintiff deadline is March 2, 2026. Similar class action notices are being issued for Beyond Meat and Phoenix Education Partners.

AGL BYND PXED securities class action false guidance misleading statements investor losses lead plaintiff deadline
Sentiment note

Company is subject to securities class action lawsuit alleging reckless issuance of unachievable 2025 guidance, material overstatement of financial impacts from strategic actions, and failure to disclose known industry headwinds. These allegations suggest management misconduct and potential investor harm.

Negative GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc
Bronstein, Gewirtz & Grossman LLC Urges agilon health, inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against agilon health, inc. (NYSE: AGL) alleging that company executives made false and misleading statements regarding 2026 guidance and overstated the financial impact of strategic risk-reduction actions. The lawsuit covers investors who purchased agilon securities between February 26, 2025 and August 4, 2025. The lead plaintiff deadline is March 2, 2026.

AGL class action lawsuit securities fraud false guidance investor harm agilon health
Sentiment note

Company is accused of issuing false 2026 guidance, overstating financial benefits from strategic actions, and making materially misleading statements about business operations and prospects, resulting in investor losses and a securities fraud class action lawsuit.

Negative GlobeNewswire Inc. • Kirby Mcinerney Llp
AGL DEADLINE NOTICE: agilon health, inc. Investors Encouraged to Contact Kirby McInerney LLP By March 2, 2026

A securities fraud class action lawsuit has been filed against agilon health, inc. for allegedly issuing false 2025 guidance and overstating the impact of strategic actions despite known industry headwinds. The CEO was terminated without cause on August 4, 2025, the same day the company suspended its full-year 2025 financial guidance. The stock price declined 51.6% following the announcement. Investors have until March 2, 2026 to apply to be lead plaintiff.

AGL securities fraud class action lawsuit false guidance CEO termination stock price decline financial misstatement lead plaintiff deadline
Sentiment note

The company is the subject of a securities fraud lawsuit alleging false and misleading statements regarding 2025 guidance and overstated financial impact from strategic actions. The CEO was terminated without cause, full-year guidance was suspended, and the stock experienced a severe 51.6% price decline on the news, indicating significant loss of investor confidence and potential material misstatements.

News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal